| Identification | More | [Name]
1-Cbz-4-hydroxymethylpiperidine | [CAS]
122860-33-7 | [Synonyms]
1-CBZ-4-HYDROXYMETHYLPIPERIDINE 1-N-CBZ-HYDROXYMETHYL-PIPERIDINE 4-HYDROXYMETHYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER BENZYL 4-(HYDROXYMETHYL)PIPERIDINE-1-CARBOXYLATE BENZYL 4-(HYDROXYMETHYL)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE BUTTPARK 75\50-51 N-(BENZYLOXYCARBONYL)-4-(HYDROXYMETHYL)PIPERIDINE N-CARBOBENZOXY-4-PIPECOLINOL N-CARBOBENZOXY-4-PIPERIDINEMETHANOL N-CARBOBENZOXY-HEXAHYDROISONICOTINOL Z-ISONICOT(H6)-OL Z-ISONIPECOTINOL Z-PIC(4)-OL 1-N-Cbz-4-Hydroxymethyl-piperidine N-Cbz-4-(hydroxymethyl)piperidine N-(Benzyloxycarbonyl)-4-(Hydroxymethyl)piperidine, 97 % | [Molecular Formula]
C14H19NO3 | [MDL Number]
MFCD02094490 | [Molecular Weight]
249.31 | [MOL File]
122860-33-7.mol |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . S36/37/39:Wear suitable protective clothing, gloves and eye/face protection . S37/39:Wear suitable gloves and eye/face protection . | [HS Code ]
2933399990 |
| Hazard Information | Back Directory | [Uses]
1-N-Cbz-hydroxymethyl-piperidine is an intermediate used in the synthesis of benzoyloxyethylpiperidinylmethylamine as fluorescent antagonists for human 5-HT4 receptors. It is also used to prepare diaminobutane derivatives as potent Ca2+-Permeable AMPA receptor antagonists. | [Synthesis]
General procedure for the synthesis of N-CBZ-4-piperidinemethanol (1-CBZ-4-hydroxymethylpiperidine) from 4-(hydroxymethyl)piperidine and benzyl chloroformate: 4-(hydroxymethyl)piperidine (2.0 g, 17.4 mmol) was dissolved in anhydrous dichloromethane (DCM, 100 mL), and the solution was cooled to 0 °C and stirred. Triethylamine (4.8 mL, 34.8 mmol) and benzyl chloroformate (3.7 mL, 34.8 mmol) were added sequentially, then the reaction mixture was slowly warmed to room temperature and stirring was continued for 2 hours. Upon completion of the reaction, the mixture was transferred to a partition funnel and layered with DCM (50 mL) and water (30 mL). The organic phase was separated and the aqueous phase was extracted with DCM (2 x 50 mL). All organic phases were combined, washed once with brine (30 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product. The crude product was purified by column chromatography using a gradient elution with hexane/EtOAc (70% to 100%) to afford 3.85 g (89% yield) of N-benzyloxycarbonyl-4-(hydroxymethyl)piperidine (E-12) as a clear oil. Its 1H NMR (CDCl3) data were as follows: δ 1.17 (m, 2H), 1.72 (m, 3H), 2.15 (br s, 1H), 2.78 (t, 2H, J = 12 Hz), 3.47 (d, 2H, J = 6.04 Hz), 4.20 (d, 2H, J = 11.68 Hz), 5.12 (s, 2H), 7.33 (m , 5H). | [References]
[1] Patent: WO2005/80394, 2005, A1. Location in patent: Page/Page column 131 [2] European Journal of Organic Chemistry, 2008, # 25, p. 4277 - 4295 [3] Patent: WO2010/46780, 2010, A2. Location in patent: Page/Page column 63-64 [4] Journal of the American Chemical Society, 2017, vol. 139, # 24, p. 8110 - 8113 [5] Patent: US2003/55244, 2003, A1 |
|
|